Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Operating Expenses (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Other Operating Expenses data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 132.3% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $3.7 million, up 30.56%, while the annual FY2025 figure was -$200000.0, 140.96% down from the prior year.
  • Other Operating Expenses reached $1.6 million in Q4 2025 per VRCA's latest filing, up from $1.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $13.6 million in Q4 2021 and bottomed at $64000.0 in Q4 2022.
  • Average Other Operating Expenses over 5 years is $1.6 million, with a median of $494000.0 recorded in 2025.
  • Peak YoY movement for Other Operating Expenses: plummeted 99.53% in 2022, then surged 4290.62% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $13.6 million in 2021, then tumbled by 99.53% to $64000.0 in 2022, then soared by 4290.62% to $2.8 million in 2023, then crashed by 74.77% to $709000.0 in 2024, then surged by 132.3% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $1.6 million in Q4 2025, $1.1 million in Q3 2025, and $494000.0 in Q2 2025.